BRPI0408749A - usos de um agente capaz de bloquear, inibir, ou melhorar a atividade mediada por vegf e de uma molécula capaz de inibir a expressão ou a atividade de vegf, e, artigo de manufatura - Google Patents

usos de um agente capaz de bloquear, inibir, ou melhorar a atividade mediada por vegf e de uma molécula capaz de inibir a expressão ou a atividade de vegf, e, artigo de manufatura

Info

Publication number
BRPI0408749A
BRPI0408749A BRPI0408749-6A BRPI0408749A BRPI0408749A BR PI0408749 A BRPI0408749 A BR PI0408749A BR PI0408749 A BRPI0408749 A BR PI0408749A BR PI0408749 A BRPI0408749 A BR PI0408749A
Authority
BR
Brazil
Prior art keywords
vegf
activity
inhibiting
blocking
article
Prior art date
Application number
BRPI0408749-6A
Other languages
English (en)
Inventor
Mark W Sleeman
Stanley J Wiegand
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of BRPI0408749A publication Critical patent/BRPI0408749A/pt
Publication of BRPI0408749B1 publication Critical patent/BRPI0408749B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"USOS DE UM AGENTE CAPAZ DE BLOQUEAR, INIBIR, OU MELHORAR A ATIVIDADE MEDIADA POR VEGF E DE UMA MOLéCULA CAPAZ DE INIBIR A EXPRESSãO OU A ATIVIDADE DE VEGF, E, ARTIGO DE MANUFATURA". Métodos de tratar diabetes em mamíferos, particularmente humanos, pelo bloqueio ou pela inibição da atividade mediada por VEGF. Um inibidor preferido de atividade mediada por VEGF é um antagonista de VEGF tal como um capturador de VEGF capaz de ligar e bloquear VEGF.
BRPI0408749A 2003-03-28 2004-03-26 uso do antagonista de vegf vegfr1r2-fc delta c1(a) BRPI0408749B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45879003P 2003-03-28 2003-03-28
PCT/US2004/009246 WO2004087206A2 (en) 2003-03-28 2004-03-26 Methods of treating diabetes by blocking vegf-mediated activity

Publications (2)

Publication Number Publication Date
BRPI0408749A true BRPI0408749A (pt) 2006-03-28
BRPI0408749B1 BRPI0408749B1 (pt) 2016-10-04

Family

ID=33131825

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408749A BRPI0408749B1 (pt) 2003-03-28 2004-03-26 uso do antagonista de vegf vegfr1r2-fc delta c1(a)

Country Status (16)

Country Link
US (1) US7052691B2 (pt)
EP (1) EP1608685B1 (pt)
JP (2) JP4730909B2 (pt)
AT (1) ATE354592T1 (pt)
AU (1) AU2004226417B2 (pt)
BR (1) BRPI0408749B1 (pt)
CA (1) CA2519787C (pt)
CY (1) CY1106530T1 (pt)
DE (1) DE602004004883T2 (pt)
DK (1) DK1608685T3 (pt)
ES (1) ES2278333T3 (pt)
MX (1) MXPA05008972A (pt)
PL (1) PL1608685T3 (pt)
PT (1) PT1608685E (pt)
SI (1) SI1608685T1 (pt)
WO (1) WO2004087206A2 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005267741A1 (en) * 2004-07-30 2006-02-09 Regeneron Pharmaceuticals, Inc. Methods of treating type I diabetes by blocking VEGF-mediated activity
HUE034109T2 (en) 2005-03-25 2018-01-29 Regeneron Pharma VEGF antagonist formulations
SI2944306T1 (sl) 2006-06-16 2021-04-30 Regeneron Pharmaceuticals, Inc. Formulacije antagonista VEGF, primerne za intravitrealno dajanje
ES2345596B1 (es) * 2009-03-26 2011-07-13 Fundacion Progreso Y Salud Composicion para la prevencion o el tratamiento de la diabetes mellitus.
US20100330098A1 (en) * 2009-06-29 2010-12-30 Kuo Calvin J Methods to regulate glucose metabolism
CN103533950A (zh) 2011-01-13 2014-01-22 瑞泽恩制药公司 Vegf拮抗剂在治疗血管生成眼病中的用途
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
NZ721607A (en) 2014-01-25 2017-05-26 Chengdu Kanghong Biotechnologies Co Ltd Fusion protein inhibiting angiogenesis or growth and use thereof
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2016008975A1 (en) 2014-07-18 2016-01-21 Sanofi Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
ITUB20169928A1 (it) * 2016-01-12 2017-07-12 Medical And Biotechnological Services In Sigla M B S Srl Formulazioni farmaceutiche per il trattamento del diabete
AU2018375398C1 (en) 2017-11-30 2026-01-15 Regeneron Pharmaceuticals, Inc. Use of a VEGF antagonist to treat angiogenic eye disorders
US12071476B2 (en) 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder
MX2022013812A (es) 2020-05-08 2022-12-15 Regeneron Pharma Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9410533D0 (en) * 1994-05-26 1994-07-13 Lynxvale Ltd In situ hybridisation and immuno-Chemical localisation of a growth factor
IL145941A (en) * 1999-04-28 2007-08-19 Univ Texas Compositions and methods for cancer treatment by selectively inhibiting vegf
US6833349B2 (en) * 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
MXPA01012630A (es) * 1999-06-08 2002-07-22 Regeneron Pharma Polipeptidos quimericos modificados con propiedades farmacocineticas mejoradas.

Also Published As

Publication number Publication date
US7052691B2 (en) 2006-05-30
DE602004004883D1 (de) 2007-04-05
MXPA05008972A (es) 2005-11-04
CA2519787A1 (en) 2004-10-14
JP2011037894A (ja) 2011-02-24
US20040213787A1 (en) 2004-10-28
PT1608685E (pt) 2007-05-31
EP1608685A2 (en) 2005-12-28
WO2004087206A3 (en) 2004-12-16
BRPI0408749B1 (pt) 2016-10-04
EP1608685B1 (en) 2007-02-21
SI1608685T1 (sl) 2007-08-31
JP4730909B2 (ja) 2011-07-20
CA2519787C (en) 2012-06-05
CY1106530T1 (el) 2012-01-25
ATE354592T1 (de) 2007-03-15
WO2004087206A2 (en) 2004-10-14
DE602004004883T2 (de) 2007-11-15
PL1608685T3 (pl) 2007-07-31
AU2004226417B2 (en) 2009-01-22
JP2006521397A (ja) 2006-09-21
DK1608685T3 (da) 2007-06-11
ES2278333T3 (es) 2007-08-01
AU2004226417A1 (en) 2004-10-14
HK1080092A1 (en) 2006-04-21

Similar Documents

Publication Publication Date Title
BR0308854A (pt) Benzazolas substituìdas e seus usos como inibidoras de quinase raf
EA200600689A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов raf киназы
CY1109906T1 (el) Παραγωγα c3-kyano εποθιλονης
UA107783C2 (en) Isoindoline compounds for use in treating cancer
BR0304648A (pt) Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia
BRPI0514841A (pt) inibidores de piridila da sinalização de hedgehog, processo de preparação dos mesmos e composição compreendendo os referidos inibidores
BRPI0409128A (pt) uso de antagonistas de opióides periféricos, especialmente metilnaltrexona para tratar sìndrome de intestino irritável
EA200970542A1 (ru) ИНГИБИТОРЫ ДЕЙСТВИЯ Akt
EA200870019A1 (ru) Лактамовые соединения и способы их применения
PL1877396T3 (pl) Dipirydylo-dihydropirazolony i ich zastosowanie, pochodne 4-(pirydyn-3-ylo)-2-(pirydyn-2-ylo)-1,2-dihydro-3H-pirazol-3-onu jako specyficzne inhibitory prolilo-4-hydroksylazy HIF do leczenia chorób układu sercowo-naczyniowego i chorób hematologicznych
TW200714604A (en) Substituted heterocycles and the uses thereof
BRPI0509172A (pt) pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento
PT1309592E (pt) Pirazoles substituidos
PH12013500578A1 (en) Substituted dihydropyrazolones for treating cardiovascular and haematological diseases
BRPI0511139B8 (pt) compostos que inibem quinase aurora e composição farmacêutica contendo os mesmos
EA200900571A1 (ru) Композиции chk1 ингибиторов
ATE376835T1 (de) Verwendung von fucanen in der behandlung von adhäsion, arthritis und psoriasis
NO20071428L (no) Kombinasjon inneholdende ZD6474 og Imatinib
BRPI0506662B8 (pt) compostos ativadores de glucoquinase
ATE520668T1 (de) Sigmarezeptor-inhibitoren
ATE421512T1 (de) Inhibitoren von mitotischem kinesin
BRPI0408902A (pt) composições de inibidores seletivos da ciclooxigenase-2 e agonistas de 5-ht 1b/1d para o tratamento e a prevenção de enxaqueca
BR0214481A (pt) Método e composição para potenciação de um analgésico opiáceo
BRPI0508254A (pt) métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos
DK1401413T3 (da) Anvendelse af tyrosinkinaseinhibitorer til behandling af allergiske sygdomme

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/10/2016, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: REFERENTE AO DESPACHO 21.6 PUBLICADO NA RPI 2559 DE 2020-01-21